Aquestive Therapeutics (NASDAQ:AQST) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Aquestive Therapeutics (NASDAQ:AQST) from a hold rating to a sell rating in a research note published on Saturday.

AQST has been the topic of several other research reports. Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a report on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $8.80.

Aquestive Therapeutics Stock Performance

NASDAQ AQST opened at $4.32 on Friday. The stock’s fifty day moving average is $4.07 and its two-hundred day moving average is $5.08. The firm has a market capitalization of $527.21 million, a P/E ratio of -5.54 and a beta of 1.54. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Wednesday, March 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The business had revenue of $13.02 million during the quarter, compared to the consensus estimate of $13.28 million. As a group, sell-side analysts forecast that Aquestive Therapeutics will post -0.46 EPS for the current year.

Insider Activity at Aquestive Therapeutics

In other Aquestive Therapeutics news, CFO A Ernest Toth, Jr. sold 58,254 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $242,919.18. Following the sale, the chief financial officer owned 376,112 shares in the company, valued at $1,568,387.04. This represents a 13.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Melina Cioffi sold 25,311 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total value of $105,546.87. Following the sale, the senior vice president owned 274,867 shares in the company, valued at approximately $1,146,195.39. This trade represents a 8.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 395,690 shares of company stock worth $1,650,027 over the last quarter. 8.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently bought and sold shares of AQST. NewEdge Advisors LLC purchased a new stake in Aquestive Therapeutics during the 3rd quarter worth about $28,000. BNP Paribas Financial Markets increased its holdings in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares during the period. Modern Wealth Management LLC acquired a new position in shares of Aquestive Therapeutics during the 2nd quarter worth about $33,000. Kestra Private Wealth Services LLC acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter worth about $60,000. Finally, Lineweaver Wealth Advisors LLC acquired a new position in shares of Aquestive Therapeutics during the 4th quarter worth about $65,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.